Skip to main content
Premium Trial:

Request an Annual Quote

Castle Biosciences Closes $20M Credit Facility

NEW YORK (GenomeWeb) – Oxford Finance and Silicon Valley Bank said today that they have closed a $20 million credit facility with Castle Biosciences.

The credit facility comprises a $15 million senior secured term loan and a $5 million line of credit. Castle Bio, which is based in Friendswood, Texas, will use the proceeds to accelerate marketing and new product development related to its molecular prognostic tests for patients with underserved cancers.

Specifically, Castle Bio offers DecisionDx-Melanoma for cutaneous melanoma, DecisionDx-UM for uveal melanoma, and DecisionDx-PRAME for a rare and aggressive eye cancer. DecisionDx-Melanoma, for example, uses RT-PCR to analyze the expression of 31 genes within melanomas, and can more accurately predict distant metastases in Stages I and II patients than can current staging factors, according to the company.

The company offers all of its tests out of its CLIA-certified, CAP-accredited laboratory in Phoenix, Arizona.

"Castle Biosciences is focused on delivering high-value tests to improve cancer treatment. This expanded capital facility will be used to accelerate growth of our cutaneous melanoma test, DecisionDx-Melanoma, and support our near-term pipeline," Castle Bio  President and CEO Derek Maetzold said in a statement.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.